ArticleCPT: pharmacometrics & systems pharmacology2022
Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.
Article in CPT: pharmacometrics & systems pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Skipping a pillar does not make for strong foundations: Pharmacokinetic-pharmacodynamic reasoning behind the shape of dose-response relationships in oncology.CPT: pharmacometrics & systems pharmacology · 2023Pooled it
- Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia.Clinical and translational science · 2024Trial
- Adaptive Dosing Trial Simulation Framework to Inform Dose Optimization: Case Study Using Longitudinal PKPD Models With PF-06804103 Phase 1 Data in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive and Low Solid Tumors.CPT: pharmacometrics & systems pharmacology · 2026Article
- Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data.CPT: pharmacometrics & systems pharmacology · 2026Article
- A tutorial on pharmacometric Markov models.CPT: pharmacometrics & systems pharmacology · 2025Article
- Nonlinear mixed-effects modeling as a method for causal inference to predict exposures under desired within-subject dose titration schemes.CPT: pharmacometrics & systems pharmacology · 2025Article
- Building an adaptive dose simulation framework to aid dose and schedule selection.CPT: pharmacometrics & systems pharmacology · 2023Article
- Mixed-effects models and the drug titration paradox.CPT: pharmacometrics & systems pharmacology · 2023Article
- Response to "mixed-effects models and the drug titration paradox".CPT: pharmacometrics & systems pharmacology · 2023Article
- Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.CPT: pharmacometrics & systems pharmacology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Response-based dose individualization or dose titration is a powerful approach to achieve precision dosing. Yet, titration as an individualization strategy is underused in drug development and therefore not reflected in labeling, possibly partly because of the data analysis challenges associated with assessing dose/exposure-response under dose titration, where there is an inherent risk of selection bias because poor responders would get high doses, whereas good responders would get low doses. In a recent article, this issue of selection bias was termed the "titration paradox." In this study, we demonstrate by means of simulation that the titration paradox may be overcome if longitudinal data from dose titration trials is analyzed using a population approach that accounts for the fact that dose/exposure-response relationships differ between individuals. We show that with an appropriate sample size and missing data missing at random, stepwise dose/exposure-response modeling based on data obtained under dose titration is not by definition subject to model selection bias or bias in parameter estimates. We also illustrate the challenges of graphical exploration of data obtained under dose titration and discuss the use of model diagnostic tools with such data. Our study shows that if, at every timepoint in the course of a trial, there is a clear causal relationship between the response and the dose/exposure level, and a population approach is used, it will in many cases be possible to develop, estimate, and appropriately qualify a dose/exposure-response model also for data obtained under dose titration, thus overcoming the titration paradox.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.